Directory
>
Wes Trotter
Wes Trotter
Senior Vice President, Drug Discovery and Pharmaceutical Development | Kronos Bio
Cambridge, Massachusetts, United States
Wes Trotter
Summary
Wes Trotter is a seasoned leader in drug discovery and pharmaceutical development, currently serving as the Senior Vice President at Kronos Bio. With over two decades of experience at Merck Research Laboratories, he has a robust background in medicinal chemistry and drug design, contributing to numerous successful clinical programs across various therapeutic areas. Wes holds a Ph.D. in Synthetic Organic Chemistry from Harvard University and has been recognized for his leadership of multi-disciplinary teams. His academic journey includes prestigious institutions such as the University of North Carolina and the University of Cambridge. Wes's expertise extends to high throughput screening and pharmacology, making him a pivotal figure in advancing drug development initiatives. He is passionate about fostering innovation in the pharmaceutical industry and mentoring the next generation of scientists. His blend of technical acumen and leadership experience positions him as a key influencer in the field.
Wes Trotter
Work Experience
Senior Vice President, Drug Discovery and Pharmaceutical Development at
Kronos Bio
February 2024 - Present
Senior Vice President, Drug Discovery at
Kronos Bio
April 2023 - Present
Vice President, Chemistry at
Kronos Bio
January 2020 - April 2023
Director, Discovery Chemistry at
Merck
October 2011 - January 2020
Chemistry Program Team Lead at
Merck
July 2009 - October 2011
Senior Research Fellow at
Merck Research Laboratories
August 1999 - July 2009
Summer Intern at
Burroughs Wellcome
January 1990 - January 1993
Wes Trotter
Education
Harvard University, Ph.D.
January 1994 - January 1999
University of Cambridge, M.Phil.
January 1993 - January 1994
University of North Carolina at Chapel Hill, B.S.
January 1989 - January 1993
NCSSM
January 1987 - January 1989
Frequently Asked Questions about Wes Trotter
What is Wes Trotter email address?
Wes Trotter's primary email address is ***********@kronosbio.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Wes Trotter work for?
Wes Trotter is a Senior Vice President, Drug Discovery and Pharmaceutical Development at Kronos Bio, a company specializing in Commercial physical research.
Where Wes Trotter graduated from?
Wes Trotter holds a degree in Synthetic Organic Chemistry from Harvard University.
How can I directly contact Wes Trotter?
To contact Wes Trotter directly, you can use the email address ***********@kronosbio.com. Complete contact information is available upon registration with Muraena.
Who is Wes Trotter?
Wes Trotter is a seasoned leader in drug discovery and pharmaceutical development, currently serving as the Senior Vice President at Kronos Bio. With over two decades of experience at Merck Research Laboratories, he has a robust background in medicinal chemistry and drug design, contributing to numerous successful clinical programs across various therapeutic areas. Wes holds a Ph.D. in Synthetic Organic Chemistry from Harvard University and has been recognized for his leadership of multi-disciplinary teams. His academic journey includes prestigious institutions such as the University of North Carolina and the University of Cambridge. Wes's expertise extends to high throughput screening and pharmacology, making him a pivotal figure in advancing drug development initiatives. He is passionate about fostering innovation in the pharmaceutical industry and mentoring the next generation of scientists. His blend of technical acumen and leadership experience positions him as a key influencer in the field.
Wes`s contact details
***********@kronosbio.com
Colleagues
President and CEO
Vice President, Discovery Biology
Board of Directors
Vice President Clinical Science
Faculty Director
VP of Finance
Chief Scientific Officer
Senior Director and Chief of Staff
Chief Administrative Officer (CAO)
Vice President Corporate Development and Investor Relations